

NCT ID	NCT05319314
Title	GCC19CART for Patients With Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2022-04-08
Location	California, United States Colorado, United States Massachusetts, United States Michigan, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	GCC19CART
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05785325
Title	RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
Phase	Phase 2
Date Added	2023-03-27
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	RC48-ADC plus Bevacizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05784688
Title	Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2023-03-27
Location	Texas, United States Washington, United States Korea, Republic of
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	TU2218 + Pembrolizumab
Tags	MSS/ MMRp
NCT ID	NCT05798533
Title	Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
Phase	Phase 1
Date Added	2023-04-04
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Cyclophosphamide, Fludarabine, Interleukin-2
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT00001823
Title	Evaluation for NCI Surgery Branch Immunotherapy Clinical Research Protocols

Phase	
Date Added	1999-11-04
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05382741
Title	Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
Phase	Phase 2
Date Added	2022-05-19
Location	Italy
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Regorafenib 30 mg capsules, Imfinzi, Stivarga
Tags	MSS/ MMRp
NCT ID	NCT05838768
Title	Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
Phase	Phase 1
Date Added	2023-05-03
Location	California, United States Massachusetts, United States New York, United States Texas, United States Belgium China France Germany Israel Italy Japan Norway Singapore South Korea Spain Sweden Taiwan United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	HRO761, Irinotecan
Tags	MSI-H/ MMRd
NCT ID	NCT05426005
Title	Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2022-06-21
Location	China

Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Cadonilimab
Tags	MSI-H/ MMRd
NCT ID	NCT03667170
Title	KN035 for dMMR/MSI-H Advanced Solid Tumors
Phase	Phase 2
Date Added	2018-09-12
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd
NCT ID	NCT05239741
Title	Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Phase	Phase 3
Date Added	2022-02-15
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	5-Fluorouracil, Irinotecan, Leucovorin, oxaliplatin
Tags	MSI-H/ MMRd